OCGN Ocugen Inc

Price (delayed)

$1.64

Market cap

$422.02M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.25

Enterprise value

$402.48M

Ocugen, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing gene therapies to cure blindness diseases and developing a vaccine to save lives from COVID-19. Its breakthrough modifier ...

Highlights
Ocugen's gross profit has surged by 141% YoY and by 17% QoQ
OCGN's revenue has soared by 141% YoY and by 17% from the previous quarter
OCGN's quick ratio has dropped by 66% year-on-year and by 29% since the previous quarter
The equity has shrunk by 60% YoY and by 25% QoQ

Key stats

What are the main financial stats of OCGN
Market
Shares outstanding
257.33M
Market cap
$422.02M
Enterprise value
$402.48M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
13.9
Price to sales (P/S)
59.84
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
57.09
Earnings
Revenue
$7.05M
EBIT
-$58.5M
EBITDA
-$57.25M
Free cash flow
-$65.63M
Per share
EPS
-$0.25
Free cash flow per share
-$0.26
Book value per share
$0.12
Revenue per share
$0.03
TBVPS
$0.2
Balance sheet
Total assets
$51.79M
Total liabilities
$21.53M
Debt
$6.83M
Equity
$30.26M
Working capital
$13.95M
Liquidity
Debt to equity
0.23
Current ratio
1.87
Quick ratio
1.64
Net debt/EBITDA
0.34
Margins
EBITDA margin
-812%
Gross margin
100%
Net margin
-829.8%
Operating margin
-851%
Efficiency
Return on assets
-83.6%
Return on equity
-117.3%
Return on invested capital
-395.3%
Return on capital employed
-163.7%
Return on sales
-829.8%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

OCGN stock price

How has the Ocugen stock price performed over time
Intraday
-1.2%
1 week
-14.14%
1 month
23.31%
1 year
172.88%
YTD
185.22%
QTD
5.81%

Financial performance

How have Ocugen's revenue and profit performed over time
Revenue
$7.05M
Gross profit
$7.05M
Operating income
-$60M
Net income
-$58.5M
Gross margin
100%
Net margin
-829.8%
Ocugen's gross profit has surged by 141% YoY and by 17% QoQ
OCGN's revenue has soared by 141% YoY and by 17% from the previous quarter
The company's operating margin has surged by 72% YoY and by 22% QoQ
The net margin has soared by 72% YoY and by 21% from the previous quarter

Growth

What is Ocugen's growth rate over time

Valuation

What is Ocugen stock price valuation
P/E
N/A
P/B
13.9
P/S
59.84
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
57.09
The EPS has grown by 36% year-on-year and by 3.8% since the previous quarter
The price to book (P/B) is 162% more than the last 4 quarters average of 5.3 and 99% more than the 5-year quarterly average of 7.0
The equity has shrunk by 60% YoY and by 25% QoQ
OCGN's revenue has soared by 141% YoY and by 17% from the previous quarter
The price to sales (P/S) is 47% more than the last 4 quarters average of 40.6

Efficiency

How efficient is Ocugen business performance
The return on sales has surged by 72% year-on-year and by 21% since the previous quarter
The ROIC has grown by 49% YoY and by 3.4% from the previous quarter
OCGN's ROE is down by 22% year-on-year and by 14% since the previous quarter
The return on assets has declined by 10% year-on-year and by 7% since the previous quarter

Dividends

What is OCGN's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for OCGN.

Financial health

How did Ocugen financials performed over time
OCGN's total assets is 141% greater than its total liabilities
OCGN's quick ratio has dropped by 66% year-on-year and by 29% since the previous quarter
The current ratio has dropped by 65% year-on-year and by 25% since the previous quarter
The debt is 77% less than the equity
The debt to equity has surged by 188% year-on-year and by 35% since the previous quarter
The equity has shrunk by 60% YoY and by 25% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.